Metabolic disorders therapy area most suitable for use of digital health tech in clinical trials: poll
Verdict has conducted a poll to assess which therapy areas are most suitable for the use of digital health technologies in clinical trials.
Simplifying Clinical Trials
Small world: how decentralisation is improving paediatric clinical trials
Paediatric trials remain among the most challenging aspects of clinical research. Clinical Trials Arena sat...
Groundbreaking UK “mega-trial” will test existing drugs as new treatments for MS
In a world-first “mega-trial”, UK experts will test a range of drugs already approved for...
Arch Biopartners secures approval to amend LSALT Peptide trial protocols
Canadian firm Arch Biopartners has secured approval to make certain protocol amendments to the Phase...
How to increase efficiency and agility in oncology trials
It’s no secret that pharmaceutical and clinical trial industries are reluctant to adapt to technological...
Why going digital is the right step for the pharma industry
There are several factors at play that explain this reticence to accept change in the pharma industry. For one, regulatory overhead is high and some organisations are reluctant to take…
How a digital approach to risk management is transforming the pharma industry
When it comes to simplifying clinical trials, the most important change companies can make is to embrace the 21st century and its digital benefits, including how they approach risk management.…
How paper protocols may be harming your clinical trial’s success
Convenient, timely access to clinical trial protocols has long been a problem in the pharmaceutical industry as these critical study documents are still largely distributed as paper documents. It’s not…
How digital transformation can bring clinical trials into the 21st century
In the digital era, we have gotten used to searching and retrieving almost any information we require within seconds. Because people asked “what if?”, we now order food delivery, manage…
Treatment-resistant rare diseases: exploring landmark drug approvals in 2020
Rare disease drug development poses such serious challenges that only 5% of rare diseases have a treatment. However, this troubling situation is improving slowly due to better communication between all the stakeholders involved in research...
